Abstract
<h3>Watch the video or read the poster to learn:</h3> <ul><li>Current regulatory guidance for residual plasmid DNA</li><li>Development and validation of a highly robust multiplexed qPCR assay for the quantitation of residual plasmid DNA carrying kanamycin resistance genes</li></ul><div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://bioinsights.blob.core.windows.net/uploads/Tania-pic-GrandCanyon copy.jpg" data-image="1"></div><div class="author-det"> <b>Tania Chakrabarty</b> is driven by a passion to improve human lives and precision medicine using cutting-edge research and new technologies. Dr Chakrabarty earned her PhD in Biophysics from the University of Illinois at Urbana-Champaign where she studied the structure-function relationship of the muscle protein myosin using fluorescence spectroscopy. Over the last decade, Dr Chakrabarty has led R&D organizations developing clinical diagnostics and RUO products at both large companies and smaller startups. She has earned several awards in her career and is an author of multiple patents. She currently leads the Pharma Analytics R&D team at Thermo Fisher Scientific, overseeing the development of quality and safety testing solutions for biopharmaceutical products </div></div></div>
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
